Medexus Pharmaceuticals (OTCMKTS:MEDXF) Shares Up 2% – Still a Buy?

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) shares shot up 2% on Thursday. The stock traded as high as $3.60 and last traded at $3.60. Approximately 3,200 shares changed hands during trading, a decline of 76% from the average daily volume of 13,145 shares. The stock had previously closed at $3.53.

Medexus Pharmaceuticals Price Performance

The business’s fifty day simple moving average is $3.56 and its 200-day simple moving average is $2.98.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company focused on acquiring, commercializing and supporting differentiated prescription products in North America. The company serves healthcare providers and patients primarily in the United States and Canada, with an emphasis on products addressing specialty and underserved therapeutic markets.

Medexus’ portfolio has included IXINITY, a recombinant factor IX replacement therapy used to prevent and control bleeding in people with hemophilia B; Rasuvo, a single-dose subcutaneous methotrexate injection used for certain rheumatoid arthritis and juvenile idiopathic arthritis patients; and Gleolan, an oral diagnostic imaging agent used during surgery to help visualize malignant glioma tissue.

The company’s business model is centered on licensing, acquiring and commercializing pharmaceutical products rather than conducting broad-based drug discovery.